Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr3.17 DKK
Change Today -0.02 / -0.63%
Volume 6.3K
NEUR On Other Exchanges
As of 11:00 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

neurosearch a/s (NEUR) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/14 - kr3.43
52 Week Low
12/30/14 - kr2.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEUROSEARCH A/S (NEUR)

Related News

No related news articles were found.

neurosearch a/s (NEUR) Related Businessweek News

No Related Businessweek News Found

neurosearch a/s (NEUR) Details

NeuroSearch A/S operates as a biopharmaceutical company in Denmark. The company’s product pipeline comprises Ordopidine and Seridopidine that are dopaminergic stabilizers, which have completed Phase I clinical studies to treat central nervous system (CNS) disease. Its drug candidates affect the CNS and are directed towards indications, such as motor disorders. The company was founded in 1989 and is based in Hellerup, Denmark.

2 Employees
Last Reported Date: 02/27/15
Founded in 1989

neurosearch a/s (NEUR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

neurosearch a/s (NEUR) Key Developments

NeuroSearch A/S Announces Earnings Results for the Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

NeuroSearch A/S announced earnings results for the quarter ended March 31, 2015. For the quarter, the company posted an operating loss of DKK 2 million compared to DKK 2 million a year ago. Loss after tax of DKK 4 million compared to a loss of DKK 2 million a year ago. In 2015, the company expects an operating loss in the range of DKK 7 million to DKK 9 million.

Neurosearch A/S Proposes Amendments to Articles of Association

Neurosearch A/S will consider proposes to amend Article 5 of the Articles of Association so that any new shares to be issued by the company shall be issued in the name of the holder. The Board of Directors proposes to extend the Board of Directors' authorisation to increase the share capital of the company until 15 April 2020 and, thus, amending Article 4 of the Articles of Association.

Neurosearch A/S Reports Audited Consolidated Earnings Results for the Year 2014; Provides Earnings Guidance for the Year 2015

NeuroSearch A/S reported audited consolidated earnings results for the year 2014. For the year, the company posted an operating loss on continuing operations of DKK 13 million compared to DKK 10 million, which was on a level with the Company's previously announced expectations of an operating loss of DKK 15 million. Posted a loss after tax on continuing operations was DKK 9 million compared to DKK 3 million a year ago. Consolidated loss was DKK 8 million compared to a profit of DKK 12 million a year ago. Diluted loss per share was DKK 0.32 compared to diluted earnings per share of DKK 0.50 a year ago. Operating loss was DKK 13,266,000 compared to DKK 9,615,000 a year ago. Diluted loss per share continuing operations of DKK 0.38 compared to DKK 0.13 a year ago. Cash out flow from operating activities was DKK 8,143,000 compared to DKK 47,103,000 a year ago. For 2015, the company expects an operating loss in the range of DKK 7-9 million. The outlook does not include any income from the possible sale of Company assets, potential income from the Company's agreements with Teva, Saniona or others, and neither does the outlook take into account a potential reversal of the provision of DKK 5 million made to cover the fine the Company has been ordered to pay.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEUR:DC kr3.17 DKK -0.02

NEUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NEUR.
View Industry Companies

Industry Analysis


Industry Average

Valuation NEUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROSEARCH A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at